Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Rancho Los Amigos National Rehabilitation Center, Downey, California

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

Sidney Kimmel Medical College, Philadelphia, Pennsylvania

UTHealth Houston / TIRR Memorial Hermann, Houston, Texas